Choksi Laboratories Ltd Upgraded to Hold as Technicals Improve and Valuation Attractiveness Increases

Technical Trends Signal Bullish Momentum

The primary catalyst for the upgrade stems from a marked improvement in the technical outlook. The technical grade has shifted from mildly bullish to outright bullish, supported by a confluence of positive signals across multiple timeframes. On a weekly basis, the Moving Average Convergence Divergence (MACD) indicator is bullish, while the monthly MACD remains mildly bearish, suggesting a potential turnaround in momentum over the medium term.

Bollinger Bands reinforce this positive stance, showing bullish trends on both weekly and monthly charts, indicating increased volatility with upward price movement. Daily moving averages also confirm a bullish bias, reflecting short-term strength in the stock price. The Know Sure Thing (KST) oscillator is bullish weekly but mildly bearish monthly, echoing the mixed but improving technical picture. Meanwhile, Dow Theory assessments show a mildly bullish weekly trend, though the monthly trend remains mildly bearish.

These technical signals collectively underpin the upgrade, suggesting that Choksi Laboratories is gaining traction among traders and technical analysts alike. The stock’s current price of ₹137.90, up from the previous close of ₹136.40, and intraday highs touching ₹143.20, further validate this momentum shift.

Valuation Remains Attractive Despite Mixed Financial Performance

Choksi Laboratories’ valuation metrics have also contributed to the upgrade. The company boasts a very attractive Enterprise Value to Capital Employed (EV/CE) ratio of 2.3, signalling that the stock is trading at a discount relative to its capital base. This valuation is favourable when compared to peers within the Healthcare Services sector, many of whom trade at higher multiples.

Return on Capital Employed (ROCE) stands at 9%, which, while modest, is sufficient to support the Hold rating given the valuation discount. The company’s Price/Earnings to Growth (PEG) ratio of 1.9 indicates that earnings growth is reasonably priced into the stock, especially considering the 26.7% rise in profits over the past year.

However, the financial performance remains flat for the quarter ended June 2026, with cash and cash equivalents at a low ₹0.21 crore and a debtor turnover ratio of 3.12 times, the lowest in recent periods. These factors temper enthusiasm but do not outweigh the valuation appeal and improving technicals.

Financial Trend: Mixed Signals with Institutional Support

While the company’s long-term fundamentals show some weaknesses, recent trends offer a more balanced view. Net sales have grown at a modest annual rate of 12.18% over the last five years, but the average EBIT to interest coverage ratio of 1.68 points to a weak ability to service debt, raising concerns about financial stability.

Institutional investors have increased their stake by 0.99% over the previous quarter, now collectively holding 7.02% of the company. This growing institutional participation suggests confidence in the company’s prospects and provides a stabilising influence on the stock price.

Despite underperforming the broader market over the past year with a -39.53% return compared to the BSE500’s 1.01% gain, Choksi Laboratories has delivered strong long-term returns. Over five and ten years, the stock has generated returns of 683.52% and 910.26% respectively, far outpacing the Sensex’s 38.25% and 173.92% returns over the same periods.

Quality Assessment: Weak Long-Term Fundamentals Offset by Recent Improvements

The quality of Choksi Laboratories’ business remains a concern, with an average ROCE of 8.64% over the long term and relatively poor growth in net sales. The company’s ability to generate consistent returns on capital is below industry standards, and its debt servicing capacity is limited, as reflected in the low EBIT to interest coverage ratio.

Nonetheless, the recent profit growth of 26.7% over the past year and increased institutional interest suggest that the company may be stabilising its fundamentals. The flat financial performance in the latest quarter is a cautionary note, but the valuation discount and improving technicals provide a rationale for the Hold rating rather than a Sell.

Conclusion: A Balanced Hold with Potential Upside from Technicals and Valuation

Choksi Laboratories Ltd’s upgrade to Hold from Sell reflects a careful balance of factors. The technical indicators have improved significantly, signalling bullish momentum that could attract further buying interest. Valuation metrics remain attractive, with the stock trading at a discount to peers and supported by a reasonable ROCE and PEG ratio.

However, the company’s long-term fundamental weaknesses, including modest sales growth and weak debt servicing ability, warrant caution. Institutional investor participation and recent profit growth provide some optimism, but flat quarterly results and low cash reserves highlight ongoing challenges.

Investors should monitor the evolving technical trends and financial performance closely, as further improvements could justify a more positive rating in the future. For now, the Hold rating reflects a cautious but constructive stance on this Healthcare Services micro-cap.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →